H

ello, everyone, and how are you today? We are just fine, thank you, especially since a charming snowfall has dusted the Pharmalot campus. Nothing like a pretty wintry scene, is there? Alas, the time has come, though, to focus on the matters at hand. This calls, of course, for a cup of stimulation — cherry chocolate decadence is our choice, for those tracking our variety — and we invite you to join us. Remember, no prescription is required. Meanwhile, here are some items of interest. Hope your day is smashing and do keep in touch …

Teva Pharmaceuticals (TEVA) released its long-awaited restructuring. Here are key details: 14,000 layoffs globally, or 25 percent of its workforce; close or sell a “significant” number of its 80 or so manufacturing plants; reprice or discontinue some generics; close or sell a “significant” number of R&D facilities and review all R&D programs; end dividends on ordinary shares and suspend annual bonuses this year. The moves are expected to save $3 billion by the end of 2019.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • “Aging” is a disease well known to the FDA. They’ve suffered from it for a long time. If I went back to grad school I would get a doctorate in archeology, as there is a wealth of fossils dwelling at the agency.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy